Pharming Group to Participate in Oppenheimer Rare Disease Summit
Pharming Group N.V. has announced its participation in the Oppenheimer Movers in Rare Disease Summit to be held in New York on December 11, 2025.
Event Details
According to the press release, Pharming Group N.V., a biopharmaceutical company listed on Euronext Amsterdam and Nasdaq, will participate in the Oppenheimer Movers in Rare Disease Summit scheduled in New York City on December 11, 2025. This invitation-only event aims to bring together innovative companies and investors focused on the field of rare diseases.
Speaking Engagement
Anurag Relan, Chief Medical Officer of Pharming, will participate in an informal discussion on the hereditary angioedema (HAE) market at 1:50 PM Eastern Time / 7:50 PM Central European Time. Interested parties can arrange one-on-one meetings with Pharming's management team by contacting investor relations or through their Oppenheimer representative.
Company Profile
Pharming Group N.V., headquartered in Leiden, the Netherlands, is dedicated to the development and marketing of innovative drugs for rare, disabling, and potentially life-threatening diseases. The company has a significant portion of its employees based in the United States.
